Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aspirin + vitamin D is a combination therapy investigated in the LEAD COVID-19 Phase 2 trial conducted by the Louisiana State University Health Sciences Center in New Orleans. The regimen consists of low-dose aspirin (81 mg daily) and high-dose vitamin D (50,000 IU weekly). Aspirin, a small molecule salicylate, acts as an irreversible inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), providing anti-inflammatory and antiplatelet effects to mitigate COVID-19-associated coagulopathy (CAC). Vitamin D is included to address vitamin D insufficiency, which is hypothesized to contribute to the prothrombotic state in severe COVID-19. The primary goal of this early intervention is to reduce hospitalization rates in newly diagnosed outpatients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aspirin + vitamin D.